Peptide QC

CJC-1295 + Ipamorelin HPLC Purity: What the Chromatogram Actually Shows

Updated · 3 cited sources · ResearchChem Research Team

Short answer: Reversed-phase HPLC separates peptide compounds by hydrophobicity on a C18 column and reports the purity figure as the percent-area-under-curve of the main peak at a specified UV wavelength, typically 214 nm or 220 nm. On a CJC-1295 + ipamorelin research stack, a correctly-run chromatogram shows two main peaks — one for CJC-1295 at a hydrophobic retention time and one for ipamorelin at a more polar retention time — plus smaller related-substance peaks that the related-impurities table identifies. A research-grade acceptance threshold is typically ≥ 98% main peak per compound, with any single impurity below 0.5%.

Why a CJC-IPA chromatogram has two main peaks

CJC-1295 and ipamorelin are separate molecules co-formulated in one vial, not a fused peptide. When the lyophilized powder is reconstituted and loaded onto a C18 reversed-phase column, each molecule elutes at its own retention time, and the chromatogram shows two independent main peaks. The purity figure on the COA is reported separately for each compound: percent-area-under-curve of the main peak divided by the total UV-absorbing peak area, at the stated wavelength.

The Jetté 2005 identification paper for CJC-1295 characterized the compound as a tetrasubstituted hGRF(1-29)-albumin bioconjugate: a modified 29-amino-acid fragment of GHRH that forms a covalent bond with endogenous serum albumin via a maleimide, with LC-MS characterization of the pre-conjugation parent peptide [1]. The parent peptide has the empirical formula C165H269N47O46 with a monoisotopic mass of 3,647.7 Da.

The Raun 1998 characterization paper for ipamorelin reported the pentapeptide sequence H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂, with an isolated main-peak purity greater than 97% by reversed-phase HPLC [2]. Ipamorelin has the empirical formula C38H49N9O5 with a monoisotopic mass of 711.4 Da — markedly smaller and more polar than CJC-1295, which is why the two compounds separate cleanly on a standard C18 method.

Reading the chromatogram, field by field

HPLC-report fields a CJC-1295 + ipamorelin COA should carry
FieldWhat it tells youWhat to check
ColumnWhich stationary phase was usedA C18 reversed-phase column (standard for peptide QC), with the column vendor and pore/particle size named
Mobile phaseThe solvent gradient that drove separationA water/acetonitrile gradient modified with 0.1% trifluoroacetic acid is the typical peptide-QC method
Flow rate and run timeHow fast solvent moved and how long the run wasTypically 0.5–1.0 mL/min with a 20–40 minute gradient
Detection wavelengthWhere UV absorbance was measuredNormally 214 nm or 220 nm — peptide bond absorbance maxima
CJC-1295 main peak (% AUC)Share of total UV-absorbing area that is the CJC-1295 peakA percentage value plus the retention time; research-grade stacks are typically ≥ 98%
Ipamorelin main peak (% AUC)Share of total UV-absorbing area that is the ipamorelin peakA separate percentage value plus the retention time; research-grade stacks are typically ≥ 98%
Related substances tableNamed or RT-labelled impurity peaks and their %Each entry under the related-impurity acceptance threshold (typically < 0.5% per single impurity)
Chromatogram imageThe visual record that supports the numbersA clear PDF or PNG with baseline, peak labels, retention-time axis, and area integration marks

See HPLC peptide purity explained for a first-principles walkthrough of how reversed-phase HPLC separates a peptide from its process-related impurities, and why area-under-curve at 214 nm is the industry-standard purity figure.

One COA or two? What a dual-peptide stack actually needs

A CJC-1295 + ipamorelin stack vial is prepared from two independently-synthesized peptide lots that are then blended and lyophilized together. The COA record for a stack can be presented either as a single combined COA that reports both peptides in one document, or as two linked lot-specific COAs — one for the CJC-1295 lot that went into the blend, and one for the ipamorelin lot. Both formats are acceptable so long as the chromatogram evidence for each compound is attached: a single stack COA with one combined chromatogram is not sufficient, because a C18 method that separates two co-formulated peptides should produce one chromatogram per compound at its own retention time.

The D'Hondt 2014 impurity-review paper (J Pharm Biomed Anal) covers the classes of related substances a peptide chromatogram can reveal — deletion sequences, incomplete deprotection, cleavage and oxidation products, dimers, and racemized residues — and why the related-substances table is more informative than the single purity percentage [3]. For a CJC-IPA stack, the related-substances table should distinguish between impurities that migrated with the CJC-1295 lot and impurities that migrated with the ipamorelin lot.

The numbers above are instrumental measurements from standard reversed-phase HPLC methods. The ResearchChem vial is supplied for in-vitro and animal research only; the paragraphs are not instructions for use.

What a passing CJC-IPA stack chromatogram looks like

  • Two clearly-resolved main peaks at distinct retention times — ipamorelin earlier (more polar), CJC-1295 later (more hydrophobic).
  • Baseline separation from the nearest related-substance peaks (resolution factor Rs ≥ 1.5 is the standard cut-off).
  • Main-peak purity ≥ 98% per compound, calculated as percent area-under-curve at the stated detection wavelength.
  • Related-substances table with every secondary peak either identified or labelled by retention time, and each single impurity below the acceptance threshold.
  • Consistent retention times across repeat column runs (±1% is typical for a well-conditioned column).
  • Legible chromatogram image included in the COA packet, not just the numeric summary.

ResearchChem sends the lot-specific COA (both the numeric summary and the chromatogram image) on request — email [email protected] with the lot number from the vial. The buy-intent companion with pricing and sourcing is at Buy CJC-1295 + Ipamorelin USA.

Frequently asked questions

What purity percent should a CJC-IPA chromatogram show?

A research-grade stack typically shows main-peak purity ≥ 98% for each compound, reported separately — one figure for CJC-1295, one figure for ipamorelin, both as percent area-under-curve at 214 nm or 220 nm.

Why are there two main peaks on the chromatogram?

CJC-1295 and ipamorelin are separate molecules co-formulated in one vial, not a fused peptide. They elute at different retention times on a C18 reversed-phase column: ipamorelin earlier (more polar, smaller) and CJC-1295 later (more hydrophobic, larger).

What is the related-substances table?

A line-by-line summary of every secondary peak on the chromatogram — deletion sequences, incomplete deprotection products, cleavage and oxidation products, dimers, racemized residues. Each entry is reported as a percent area-under-curve and compared to an acceptance threshold (typically < 0.5% for any single impurity).

Can one COA cover both peptides, or do I need two?

Either is acceptable, so long as a separate chromatogram and a separate purity figure appear for each compound. A single combined COA that reports both peptides but attaches only one chromatogram is not sufficient.

What wavelength should the UV detector be set to?

Typically 214 nm or 220 nm — the absorbance maxima of the peptide bond. Those wavelengths let the detector register all peptide-containing species on the chromatogram, including process-related impurities that lack a specific chromophore.

Cited studies

  1. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.. Endocrinology. 146(7):3052-3058 (2005). PubMed 15817669 DOI
  2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue.. Eur J Endocrinol. 139(5):552-561 (1998). PubMed 9849822 DOI
  3. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines.. J Pharm Biomed Anal. 101:2-30 (2014). PubMed 25044089 DOI

Related compounds

Keep reading

Research use only. ResearchChem products are laboratory reagents for in-vitro research. They are not for human or veterinary consumption and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published research for educational purposes and is not medical advice.